Antiviral agents have been developed that can counter any virus.
Emergency news!
Antiviral agents have been developed that can counter any virus.
In 2020, We are under the threat of COVID-19 (2019-nCoV, SARS-CoV-2).
The countermeasures against this virus are the invention of new medicine or the development of vaccines.
The antiviral agent was invented in Japan, and the content of the patent that was applied was announced in February 2019
Its component is proteoglycan.
This patent describes that proteoglycans are antiviral agents.
This is the top page of the patent document.
The patent information is written in Japanese, so I will introduce it in English.
The title of the patent publication is "antiviral agent"
The summary is "An antiviral agent containing at least one selected from the group consisting of sugar chain-peptide separation of proteoglycan"
This is the experimental data published in the patent publication.
"1-4. Use" is written as "the virus targeted by the antiviral agent of the present invention is not particularly limited."
Examples of target viruses described in "1-4. Usage" are as follows.
For example,
Influenza virus (eg type A, type B, etc.)
Rubella virus
Ebola virus
Coronavirus
Measles virus
Varicella-zoster virus
Herpes virus
Mumps virus
Arbovirus
RS virus
SARS virus
Hepatitis virus (eg, hepatitis B virus, hepatitis C virus, etc.)
Yellow fever virus
AIDS virus
Rabies virus
Hantavirus
Dengue virus
Nipah virus
Envelope viruses such as Lyssa virus (viruses with envelopes)
Adenovirus
Norovirus
Rotavirus
Human papillomavirus
Polio virus
Enterovirus
Coxsackie virus
Human parvovirus
Encephalomyocarditis virus
Polio virus
Examples include non-enveloped viruses such as rhinovirus (viruses having no envelope).
This patent was announced in February 2019.
There is no reference to SARS-CoV-2 in this document as the application was filed before SARS-CoV-2 occurred. However, it is written that there are no restrictions on the target virus, and it is effective against influenza viruses and existing coronaviruses, so we can have many expectations.
According to this patent document, proteoglycans can be used as an antiviral agent for living body applications and article applications.
When it is applied to the living body, it includes medicines, cosmetics, detergents, food compositions, oral compositions, health promoters, dietary supplements and the like.
By applying the antiviral agent of the present invention to a living body, an antiviral effect (for example, virus inactivation) can be exerted at the site where the active ingredient contacts.
When the use is cosmetics, for example, liquids, gels, creams, ointments, sticks, etc.
When the use is a composition for oral cavity (including pharmaceuticals), for example, any form such as solid (tablet, particulate, capsule, film, etc.), more specifically, food (for example, Such as film).
In addition, "the antiviral agent of the present invention may further contain other components as necessary. Examples of the other components include medicines, cosmetics, food compositions, oral compositions, health-enhancing agents, It is not particularly limited as long as it is an ingredient that can be added to nutritional supplements (such as supplements). "
Therefore, it is said that it is effective even for food and drink mixed with proteoglycan.
The following contents are written in paragraphs 77 and 78.
[0077]
The content of the active ingredient of the antiviral agent of the present invention depends on the type of the active ingredient, the use, the mode of use, the application target, the state of the application target, and the like, but is not limited to, for example, 0.000001 to 100 weight%, Preferably 0.001 to 50% by weight.
[0078]
The application (for example, administration, ingestion, inoculation, etc.) amount of the antiviral agent of the present invention is not particularly limited as long as it is an effective amount that exhibits a desired effect.Usually, the weight of the active ingredient is generally 0.1 to 1000 mg / kg body weight per day. It is preferable to administer the above-mentioned dose once a day or in 2 to 3 divided doses, and the dose may be appropriately adjusted depending on the age, disease state, and symptom.
A preferred content is at least 0.001% by weight, which means 0.1 mg / kg / day is the preferred minimum line,
If you have 100% proteoglycans
Taking a 100kg person as an example, 0.0100mg to 50g
Taking a 50kg person as an example, 0.0050mg to 25g
It means that if you can eat the above amount, you will get the effect.
Currently, studies on whether proteoglycan can counter COVID-19 (2019-nCoV, SARS-CoV-2) as an antiviral agent are being conducted, but It is known that proteoglycan has the effect of activating NK cells (see this page for details), Proteoglycan has the ability to strongly resist infectious diseases due to the effects of antiviral agents and NK cell activation.
Are you interested in Proteoglycans?
If you want to get it, visit this page.